Buy Viropil

Viropil

What Is Viropil?

Viropil is a fixed-dose combination pill that contains three active ingredients-dolutegravir, lamivudine, and tenofovir disoproxil fumarate (TDF). The tablet is supplied in a single strength of 50 mg / 300 mg / 300 mg (dolutegravir / lamivudine / TDF) and is prescribed for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. In the United Kingdom the product is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available only with a prescription.

How Viropil Works in the Body

Viropil combines three agents that target different steps of the HIV replication cycle:

• Dolutegravir - an integrase strand-transfer inhibitor (INSTI). It blocks the viral integrase enzyme, preventing integration of HIV DNA into the host genome. This halts the establishment of new infected cells and reduces viral load rapidly.

• Lamivudine - a nucleoside reverse-transcriptase inhibitor (NRTI). After intracellular phosphorylation, it mimics natural nucleosides and is incorporated into viral DNA, causing premature chain termination during reverse transcription.

• Tenofovir Disoproxil Fumarate - a nucleotide reverse-transcriptase inhibitor (NtRTI). Once converted to its active diphosphate form, it competes with the natural substrate, also causing chain termination.

By acting on both the integrase enzyme and the reverse-transcriptase pathway, Viropil delivers potent antiviral activity while limiting the chance of resistance development.

Conditions Treated by Viropil

Viropil is approved in the UK for treatment-naïve adults with HIV-1 and for switching stable patients to a single-pill regimen when virologic suppression has been achieved with other regimens. The combination is intended for use as part of a complete antiretroviral therapy (ART) program, together with regular clinical monitoring.

Typical patient groups include:

• Adults (≥ 18 years) newly diagnosed with HIV-1 who have no known resistance to any of the three components.
• Adults already suppressed on a regimen containing the same three drugs, who wish to reduce pill burden.

Patient Suitability and Contraindications

Who Should Use Viropil?

• Individuals with confirmed HIV-1 infection who are treatment-naïve or stable on a compatible regimen.
• Patients with adequate renal function (creatinine clearance ≥ 50 mL/min) for the tenofovir component.
• Adults who can adhere to a once-daily dosing schedule.

Absolute Contraindications

• Known hypersensitivity to dolutegravir, lamivudine, tenofovir DF, or any excipients in the tablet.
• Severe renal impairment (creatinine clearance < 30 mL/min) - tenofovir DF should be avoided.
• Co-administration with didanosine (due to increased risk of pancreatitis).

Relative Contraindications & Special Populations

• Pregnancy: Dolutegravir carries a fetal risk warning for neural-tube defects when used in the first trimester. The benefits and risks should be weighed carefully, and alternatives considered when appropriate.
• Breastfeeding: Tenofovir and lamivudine are excreted in breast milk; continuation is generally acceptable if the mother requires ART, but infant monitoring is advised.
• Elderly patients: Age-related decline in renal function may necessitate dose adjustment or alternative therapy.
• Hepatitis B co-infection: Lamivudine and tenofovir have activity against hepatitis B virus. Discontinuation without a suitable alternative can precipitate hepatitis B flare-ups.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Headache - frequently reported, usually mild and transient.
• Nausea or abdominal discomfort - often improves after a few days.
• Insomnia - occasional, more common with dolutegravir.
• Fatigue - mild, may lessen with continued therapy.

These reactions are generally self-limiting; patients should stay hydrated and maintain a regular meal schedule.

Serious Adverse Events

• Renal toxicity - tenofovir DF can cause proximal tubular dysfunction and, rarely, acute kidney injury. Monitor serum creatinine and phosphate.
• Liver enzyme elevation - especially in patients co-infected with hepatitis B or C.
• Hypersensitivity reactions - rash, fever, or Stevens-Johnson syndrome demand immediate medical attention.
• Neuropsychiatric effects - rare but may include depression or anxiety with dolutegravir; discontinue if severe.

Drug Interactions

• Antacids containing aluminum or magnesium, and supplements with calcium or iron - bind dolutegravir and reduce its absorption. Separate dosing by at least 2 hours.
• Rifampicin - induces metabolism of dolutegravir, potentially lowering its concentration; dose adjustment of dolutegravir may be required.
• Coadministration with other nephrotoxic agents (e.g., NSAIDs, certain antivirals) - may increase risk of renal impairment; monitor kidney function closely.
• Drugs cleared by the UGT1A1 pathway - dolutegravir is a substrate; agents that inhibit UGT1A1 (e.g., atazanavir) can raise dolutegravir levels.

Food and Lifestyle Interactions

• Take with food - a moderate-fat meal increases dolutegravir exposure and improves tolerability. Tenofovir DF may also be taken with food to reduce gastrointestinal upset.
• Alcohol - does not directly affect Viropil’s pharmacokinetics but excessive intake can impair adherence and liver health.
• Driving and machinery - patients experiencing dizziness or insomnia should assess their ability to operate vehicles safely.

How to Take Viropil

• Standard dosing: One tablet (50 mg dolutegravir / 300 mg lamivudine / 300 mg TDF) once daily, with or without food.
• Renal adjustment: For creatinine clearance 30-49 mL/min, the tenofovir component should be omitted or the regimen switched to an alternative; Viropil is not recommended.
• Missed dose: If a dose is missed and it is less than 12 hours since the usual time, take the tablet as soon as remembered. If more than 12 hours have passed, skip the missed dose and resume the regular schedule. Do not double-dose.
• Overdose: Symptoms may include nausea, vomiting, abdominal pain, and lethargy. Seek emergency medical care; there is no specific antidote. Supportive treatment is the mainstay.
• Discontinuation: Switching away from Viropil should be done under medical supervision to avoid loss of viral suppression. No tapering is required, but a new ART regimen must be initiated promptly.

Monitoring and Follow-Up

• Baseline labs: HIV viral load, CD4 + cell count, serum creatinine, phosphate, liver transaminases, hepatitis B and C serology (if indicated).
• Routine monitoring:
• HIV viral load every 3-4 months until suppression, then every 6-12 months.
• Renal function (serum creatinine, eGFR) at baseline and at least every 6 months, more frequently if risk factors exist.
• Liver enzymes annually or as clinically indicated.
• Pregnant patients: Close obstetric follow-up and HIV viral load monitoring each trimester.
• Patients should contact their healthcare provider if they experience new or worsening side effects, signs of renal dysfunction (e.g., decreased urine output, swelling), or unexplained fever.

Storage and Handling

• Store the tablets at controlled room temperature (15-30 °C), protected from light and moisture.
• Keep the bottle tightly capped and out of reach of children.
• Do not use the medication after the expiry date printed on the packaging.
• Unused tablets should be disposed of according to local pharmacy return schemes or the MHRA’s “no-rinse” disposal instructions.

Medication-Specific Glossary

Integrase Strand-Transfer Inhibitor (INSTI)

A class of antiretrovirals that block the HIV integrase enzyme, preventing the insertion of viral DNA into the host genome.

Nucleoside Reverse-Transcriptase Inhibitor (NRTI)

Analogs of natural nucleosides that, once phosphorylated inside cells, terminate the DNA chain during reverse transcription.

Nucleotide Reverse-Transcriptase Inhibitor (NtRTI)

Similar to NRTIs but already contain a phosphate group; tenofovir disoproxil fumarate is a pro-drug of the active nucleotide.

Viral Load

The amount of HIV RNA copies per millilitre of blood; a key marker of treatment effectiveness.

Medical Disclaimer

This article provides educational information about Viropil and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.